$PLX News
Last published 1d ago
- 1d agoPLXSTIFEL 2026 HEALTHCARE CONFERENCE - PROTALIX BIOTHERAPEUTICS INCEarnings Call TranscriptsAll right. Good afternoon. Thanks for being here for the Stifel Healthcare Conference. My name is Colleen Cousy. I'm one of the senior analysts here at Stifle, and I'm pleased to have with us the Protallix team, includin
- 1d agoPLXProtalix Biotherapeutics Third Quarter 2026 Financial and Business Results Conference Call - PROTALIX BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the Protallix Biotherapeutics third quarter 2026 financial and business results conference call. As a reminder, this conference is being recorded. I will now turn the co
- 1d agoPLXProtalix Biotherapeutics Third Quarter 2026 Financial and Business Results Conference Call - PROTALIX BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the Protallix Biotherapeutics third quarter 2026 financial and business results conference call. As a reminder, this conference is being recorded. I will now turn the co
- 1d agoPLXProtalix BioTherapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoPLXProtalix BioTherapeutics Reports Third Quarter 2026 Financial and Business ResultsPR NewswireCompany to host conference call and webcast today at 8:00 a.m. ET Total revenues increased by $32.0 million year to date to $75.6 million, from $43.6 million...
- 2d agoPLXHigher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer DurationsPR NewswireProtalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled Gout The Company previously...
- 2w agoPLXProtalix BioTherapeutics to Present at the Stifel 2026 Healthcare ConferencePR NewswireCARMIEL, Israel, Oct. 26, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative
- 2mo agoPLXProtalix BioTherapeutics to Participate in Upcoming September 2026 Investor ConferencesPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and...
- 3mo agoPLXProtalix Biotherapeutics Second Quarter 2026 Financial and Business Results Conference Call - PROTALIX BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the Protallix Biotherapeutics second quarter 2026 financial and business results conference call. As a reminder, this conference is being recorded. I will now turn the c
- 3mo agoPLXProtalix Biotherapeutics Second Quarter 2026 Financial and Business Results Conference Call - PROTALIX BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the Protallix Biotherapeutics second quarter 2026 financial and business results conference call. As a reminder, this conference is being recorded. I will now turn the c
- 3mo agoPLXProtalix BioTherapeutics Reports Second Quarter 2026 Financial and Business ResultsPR NewswireCompany to host conference call and webcast today at 8:00 a.m. EDTRevenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily
- 3mo agoPLXProtalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and...
- 6mo agoPLXProtalix Biotherapeutics First Quarter 2026 Financial and Business Results Conference CallPROTALIX BIOTHERAPEUTICS INCEarnings Call TranscriptsGood morning, ladies and gentlemen, and welcome to the Protallix Biotherapeutics First Quarter 2026 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the co
- 6mo agoPLXProtalix BioTherapeutics Reports First Quarter 2026 Financial and Business ResultsPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and...
- 6mo agoPLXProtalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and...
- 7mo agoPLXProtalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and...
- 8mo agoPLXProtalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and...
- 8mo agoPLXChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) ▼GlobeNewswireApproved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those stable with an enzyme
- 8mo agoPLXChiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)GlobeNewswireThis press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for Elfabrio is not approved in the US. In the US, the FDA-approved dosing regimen
- 8mo agoELLOPLXEllomay Capital Announces Changes in its Principal Shareholders and Board CompositionGlobeNewswireTel-Aviv, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) ("Ellomay" or the "Company"), a renewable energy and power generator and developer of renewable energy and power
- 9mo agoPLXChiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EUGlobeNewswireCommittee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by
- 9mo agoPLXChiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EUGlobeNewswireCommittee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If approved by
- 10mo agoPLXProtalix BioTherapeutics Letter to StockholdersPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and...
- 10mo agoPLXProtalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option AgreementPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and...
- 12mo agoPLXProtalix BioTherapeutics Reports Third Quarter 2025 Financial and Business ResultsPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXChiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EUGlobeNewswirePARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group, and Protalix BioTherapeutics, Inc. (NYSE:PLX), have requested a re-examination of
- 1y agoPLXChiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EUGlobeNewswirePARMA, Italy and CARMIEL, Israel, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare
- 1y agoPLXProtalix BioTherapeutics to Present at Investor Summit VirtualACCESS NewswireCARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic
- 1y agoPLXProtalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferencePR NewswireProtalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPLXProtalix BioTherapeutics Reports Second Quarter 2025 Financial and Business ResultsPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial OfficerPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYCPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics Reports First Quarter 2025 Financial and Business ResultsPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business ResultsPR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor ConferencePR NewswireProtalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXProtalix BioTherapeutics Issues 2025 Letter to StockholdersPR NewswireProtalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 1y agoPLXChiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfaPR NewswireChiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with...
- 1y agoPLXChiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfaPR NewswireChiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with...
- 1y agoPLXProtalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoPLXProtalix BioTherapeutics Reports Third Quarter 2024 Financial and Business ResultsPR NewswireProtalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 2y agoPLXProtalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024PR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 2y agoPLXProtalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024PR NewswireProtalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...
- 2y agoPLXProtalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferencePR NewswireProtalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...